| Name | Title | Contact Details |
|---|
Stemtech Healthsciences is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The combination of Tufts Health Plan and Harvard Pilgrim Health Care represents the coming together of two of New England`s most iconic nonprofit health care companies. Representing nearly 90 years of combined service to our members and the community, together we are building upon our diverse legacies and innovative collaboration by making it our purpose to guide and empower healthier lives for everyone — no matter their age, health, race, identity, or income. That`s why we`ve named our new corporate entity Point32Health. The Point32Health name is inspired by the 32 points on a compass. It speaks to the critical role we play in guiding and empowering the people we serve to achieve healthier lives. Point32Health is our corporate name. Harvard Pilgrim Health Care, Tufts Health Plan and our other brands will continue to show up as they do today—trusted, high-quality health plans for people across the country. As Point32Health, we strive to be a different kind of nonprofit health and well-being company, with a broad range of health plans, and innovative tools that make navigating health and well-being easier, guiding our members at every step of their health care journey to better health outcomes. We are committed to providing high-quality and affordable health care, improving the health and wellness of our members, and creating healthier communities across the country.
Excedrin is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Children First Home Health Care System is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.